

REPLIDYNE INC  
Form 8-K  
June 06, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 6, 2008 (June 5, 2008)**

**REPLIDYNE, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

*(State or other jurisdiction of  
incorporation or organization)*

**1450 Infinite Drive,  
Louisville, Colorado**

*(Address of principal  
executive offices)*

**000-52082**

*(Commission File Number)*

**84-1568247**

*(I.R.S. Employer  
Identification No.)*

**80027**

*(Zip Code)*

**303-996-5500**

*(Registrant's telephone number, including area code)*

**Not Applicable**

*(Former name, former address and former fiscal year, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.05 Costs Associated with Exit or Disposal Activities**

On June 5, 2008, Replidyne, Inc. (the Company ) commenced and completed a restructuring of its operations pursuant to which it will incur approximately \$0.7 million of expense representing cash expenditures for employee related severance benefits pertaining to the termination of the employment of 12 employees. Actions by the Company related to this restructuring were completed on June 5, 2008.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**REPLIDYNE, INC.**

Dated: June 6, 2008

By: /s/ Mark L. Smith  
Mark L. Smith  
Chief Financial Officer Principal  
Accounting Officer